Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma

Author： Hashmi Mehmood H   Van Veldhuizen Peter J  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.10, Iss.5, 2010-05, pp. : 807-817

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab in the treatment of non-Hodgkin's lymphoma – a critical evaluation of randomized controlled trials

By Griffin Morag Meriel   Morley Nick  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 5, 2013-08 ,pp. : 803-811

Informa Healthcare

Access to resources Recommend Favorite

Prognosis markers for metastatic renal cell carcinoma: quantitative proteomics approach

By Dihazi Hassan  

Expert Review of Proteomics, Vol. 10, Iss. 1, 2013-02 ,pp. : 21-24

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules

By Pal Sumanta Kumar   Figlin Robert A  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 11, 2010-11 ,pp. : 1517-1520

Informa Healthcare

Access to resources Recommend Favorite

Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma

By Walter Martina   Heinze Christian   Steiner Thomas   Pilchowski Rico   von Eggeling Ferdinand   Wunderlich Heiko   Junker Kerstin  

Archives of Physiology and Biochemistry, Vol. 116, Iss. 4-5, 2010-12 ,pp. : 197-207

Informa Healthcare

Access to resources Recommend Favorite

Immunotherapy for HIV-associated non-Hodgkin's lymphoma

By Newsom-Davis Thomas   Ahamed Eliyaz   Bower Mark  

Expert Opinion on Biological Therapy, Vol. 9, Iss. 10, 2009-10 ,pp. : 1313-1324

Informa Healthcare

Access to resources Recommend Favorite